Introduction: Tuberculosis (TB) remains the leading cause of death from a curable infectious
disease; drug-resistant TB threatens to dismantle all prior gains in global control. Suboptimal …

Tuberculosis (TB) has survived for millennia due to its unique physiochemical properties
and its ability to persist in a “dormant” state. Because of these unique properties, the …

Introduction: Tuberculosis remains a global health problem and pharmacokinetic variability
has been postulated as one of the causes of treatment failure and acquired drug resistance …

Background Tuberculosis remains the major public health problem besides tremendous
efforts to combat it. Most tuberculosis patients are treated with a standard dose of first-line …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent. The
currently used combination drug regimens produce cure rates that exceed 95%, given good …

Introduction Tuberculosis (TB) remains one of the world's deadliest communicable diseases.
Although cure rates of the standard four-drug (rifampicin, isoniazid, pyrazinamide …

With an estimated 1.7 million deaths attributed to it each year, tuberculosis (TB) is the single
leading infectious cause of death in the world. Combined chemotherapy has been the …

To tackle the global TB epidemic effectively, novel treatment strategies are critically needed
to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …